

# NEXT GENERATION MIGRAINE THERAPIES

AMERICAN HEADACHE SOCIETY

**Saturday, April 6, 2019**  
**Sheraton San Diego Hotel  
& Marina-Bay Tower**  
**San Diego, California**

**Saturday, May 18, 2019**  
**Westin Galleria Dallas**  
**Dallas, Texas**

**Saturday, June 8, 2019**  
**Marriott Marquis New York**  
**New York, New York**



[www.AmericanHeadacheSociety.org](http://www.AmericanHeadacheSociety.org)

**NO COST TO HEALTHCARE PROFESSIONALS!**

All programs are scheduled from 7:45 am - 4:30 pm (subject to change)

# NO COST TO HEALTHCARE PROFESSIONALS

The Next Generation Migraine Therapies program is being offered to healthcare professionals at NO COST and will focus on providing only new and clinically relevant information via a series of didactic lectures, reviews of case studies, and interactive question-and-answer periods that will enhance basic understanding and improve prescribing techniques.

**CME Statement:** AHS is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to sponsor continuing medical education for physicians. AHS takes responsibility for the content, quality, and scientific integrity of this CME activity. AHS designates AMA PRA Category 1 credit(s)<sup>™</sup> for this medical education activity, Next Generation Migraine Therapies, for a maximum of 7.5 credits. Each physician should claim credit commensurate with the extent of their participation in the activity.

For more information, call 856-423-0043 or email [AHSHQ@talley.com](mailto:AHSHQ@talley.com). For complete program information and to register, visit [www.AmericanHeadacheSociety.org](http://www.AmericanHeadacheSociety.org)

For more information, please call 856-423-0043 or email [AHSHQ@talley.com](mailto:AHSHQ@talley.com)

For complete program information and to register, please visit [www.AmericanHeadacheSociety.org](http://www.AmericanHeadacheSociety.org)

The Next Generation Migraine Therapies Program is Supported by an Education Grant from: Allergan, Amgen, eNeura, Lilly, and Teva.

# NEXT GENERATION


---

## MIGRAINE THERAPIES

---

AMERICAN HEADACHE SOCIETY

### DATES AND LOCATIONS



Saturday, April 6, 2019

Sheraton San Diego Hotel  
& Marina-Bay Tower  
1590 Harbor Island Drive  
San Diego, CA 92101

Saturday, May 18, 2019

Westin Galleria Dallas  
13340 Dallas Parkway  
Dallas, TX 75240

Saturday, June 8, 2019

Marriott Marquis New York  
1535 Broadway  
New York, NY 10036.

## MORNING PROGRAM

### CURRICULUM DEVELOPERS

#### PROGRAM CHAIRS

Richard B. Lipton, MD, FAHS  
Albert Einstein College of Medicine

Stephen D. Silberstein, MD, FAHS  
Thomas Jefferson University

#### COMMITTEE

Jessica Ailani, MD, FAHS  
Georgetown University Hospital

Dawn C. Buse, PhD, FAHS  
Albert Einstein College of Medicine

David W. Dodick, MD, FAHS  
Mayo Clinic Arizona

Deborah I. Friedman, MD, MPH, FAHS  
University of Texas Southwestern

Peter J. Goadsby, MD, PhD, FAHS  
University of California San Francisco

Rashmi B. Halker, MD, FAHS  
Mayo Clinic Arizona

Michael J. Marmura, MD, FAHS  
Thomas Jefferson University

Lawrence C. Newman, MD, FAHS  
New York University Langone Medical Center

Scott W. Powers, PhD, ABPP, FAHS  
Cincinnati Children's Hospital Medical Center

R. Allan Purdy, MD, FAHS  
Dalhousie University

Matthew S. Robbins, MD, FAHS  
Cornell University

Todd J. Schwedt, MD, MSCI, FAHS  
Mayo Clinic Arizona

Stewart J. Tepper, MD, FAHS  
Geisel School of Medicine at Dartmouth

### EDUCATIONAL OBJECTIVES

Upon completion of this program, participants will be better able to:

- Recognize the lack of awareness of the basic science and therapeutic potential of CGRP mAbs in the prevention of migraine.
- Identify mAbs, particularly CGRP and its receptor, provide effective prophylaxis of migraine.
- Address the need for greater understanding of how to apply new information about migraine pathophysiology to specific patients and potential treatments.
- Review data on the effectiveness and safety of mAbs in the treatment of migraine and learn how results in key subpopulations can help them predict which patients are likely to respond to treatment with CGRP mAbs.

### PROGRAM

7:00 am – 7:45 am Course Registration and Continental Breakfast

**7:45 am – 8:00 am Introduction, Program Overview and Pre-test**

**8:00 am – 9:00 am State of the Art**

Upon completion of this session, participants will be better able to:

- Review diagnostic criteria for migraine and the progression of episodic migraine to chronic migraine.
- Understand the epidemiology of migraine and the impact of migraine on daily life.
- Discuss migraine pathophysiology.

8:00 am – 8:20 am Episodic and Chronic Migraine: Diagnosis, Differential Diagnosis, Epidemiology, and Impact

(cont.)

**MORNING PROGRAM**

**PROGRAM (cont.)**

8:20 am – 8:45 am Pathophysiologic Foundations of New Therapeutics (applied pathophysiology)  
 8:45 am – 9:00 am Q&A

**9:00 am – 9:50 am Next Generation Acute Treatment: Addressing Unmet Needs**

*Upon completion of this session, participants will be better able to:*

- Identify unmet needs and discuss current treatments in acute migraine therapy.
- Recognize common comorbid conditions reported in migraine and resulting implications for clinical practice.
- Discuss novel treatments in acute migraine therapy.

9:00 am – 9:10 am Current Treatment & Unmet Needs  
 9:10 am – 9:20 am Unmet Needs: Speed, Consistency, Nausea, Poor Oral Absorption (Novel Approaches for Delivering Triptans, Ergots, NSAIDs and Other Acute Treatments)  
 9:20 am – 9:35 am Cardiovascular Safety: Gepants (Small Molecule CGRP Receptor Blockers) and 5-HT<sub>1F</sub> (Lasmiditan)  
 9:35 am – 9:50 am Q&A

**9:50 am – 10:10 am Break**

**10:10 am – 12:00 pm Next Generation Preventive Treatment**

*Upon completion of this session, participants will be better able to:*

- Review current patterns of use of preventive medications.
- Discuss advantages of new drug targets (eg, mAbs) for preventive therapy.
- Determine the different neurostimulation techniques available for migraine prevention.
- Examine behavioral intervention techniques.

10:10 am – 10:25 am Current Treatment and Unmet Needs  
 10:25 am – 10:40 am Immunology, Antibodies and Monoclonal Antibodies  
 10:40 am – 11:10 am Antibodies to CGRP and its Receptors  
 11:10 am – 11:20 am Q&A  
 11:20 am – 11:35 am Neuromodulation  
 11:35 am – 11:50 am Behavioral  
 11:50 am – 12:00 pm Q&A

**12:00 pm – 1:15 pm Working Lunch: Case Discussions**  
 All Faculty

# WORKSHOP 1:

## Procedures: Nerve Blocks and OnabotulinumtoxinA

# NEXT GENERATION

## MIGRAINE THERAPIES

AMERICAN HEADACHE SOCIETY

**1:15 pm – 4:30 pm**

### Procedures, Devices and Non-pharmacological Treatment Workshops

Attendees will be broken into two (2) groups. Each group will be assigned a workshop initially and then switch to the other at the break allowing attendees to attend both workshops.

## CURRICULUM DEVELOPERS

### PROGRAM CHAIRS

Richard B. Lipton, MD, FAHS  
Albert Einstein College of Medicine

Stephen D. Silberstein, MD, FAHS  
Thomas Jefferson University

### COMMITTEE

Matthew S. Robbins, MD, FAHS  
Cornell University

## PROGRAM

**1:15 pm – 2:45 pm**

### Workshop 1: Procedures: Nerve Blocks and OnabotulinumtoxinA

1:15 pm - 2:00 pm  
2:00 pm - 2:45 pm

Nerve Blocks and OnabotulinumtoxinA with Q & A  
Headache Procedures hands-on training

**2:45 pm - 3:00 pm**

### Break

(attendees switch rooms-workshops repeat)

**3:00 pm – 4:30 pm**

### Workshop 1: Procedures: Nerve Blocks and OnabotulinumtoxinA

3:00 pm - 3:45 pm  
3:45 pm - 4:30 pm

Nerve Blocks and OnabotulinumtoxinA with Q & A  
Headache Procedures hands-on training

*Upon completion of this session, participants will be better able to:*

- Identify patients with headache disorders who are candidates for peripheral nerve blocks, trigger point injections, and onabotulinumtoxinA injections.
- Gain an understanding of anatomical landmarks enabling safe and effective procedural headache therapy.
- Perform peripheral nerve blocks, trigger point injections, and onabotulinumtoxinA injections on models to optimize use in clinical practice.

This Workshop will highlight the role of nerve blocks, stimulators, and OnabotulinumtoxinA in the treatment of migraine and chronic migraine. The workshop will include a didactic session coupled with hands-on training.

# WORKSHOP 2:

## Nonpharmacologic Treatments: Devices and Behavioral Enhancements to Migraine Management

# NEXT GENERATION MIGRAINE THERAPIES

AMERICAN HEADACHE SOCIETY

**1:15 pm - 4:30 pm**

### Procedures, Devices and Non-pharmacological Treatment Workshops

Attendees will be broken into two (2) groups. Each group will be assigned a workshop initially and then switch to the other at the break allowing attendees to attend both workshops.

## CURRICULUM DEVELOPERS

### PROGRAM CHAIRS

Richard B. Lipton, MD, FAHS  
Albert Einstein College of Medicine

Stephen D. Silberstein, MD, FAHS  
Thomas Jefferson University

### COMMITTEE

Dawn C. Buse, PhD, FAHS  
Albert Einstein College of Medicine

Peter J. Goadsby, MD, PhD, FAHS  
University of California San Francisco

Rashmi B. Halker, MD, FAHS  
Mayo Clinic Arizona

## PROGRAM

**1:15 pm - 2:45 pm**

### Workshop 2: Nonpharmacologic Treatments: Devices and Behavioral Enhancements to Migraine Management

1:15 pm - 2:00 pm  
2:00 pm - 2:45 pm

Current Devices and Devices to come with Q & A  
Behavioral Enhancements to Migraine Management with Q & A

**2:45 pm - 3:00 pm**

**Break**  
(attendees switch rooms-workshops repeat)

**3:00 pm - 4:30 pm**

### Workshop 2: Nonpharmacologic Treatments: Devices and Behavioral Enhancements to Migraine Management

3:00 pm - 3:45 pm  
3:45 pm - 4:30 pm

Current Devices and Devices to come with Q & A  
Behavioral Enhancements to Migraine Management with Q & A

Upon completion of this session, participants will be better able to:

- Assess patients who have contradictions to standard migraine treatments and may be candidates for alternative treatment strategies.
- Screen and identify patients who fail standard and preventative therapies and may be at risk of developing medication overuse or headache status deterioration.
- Utilize alternative neuromodulating treatments to reduce the severity, disability, and pain associated with migraine and other headache disorders.

This Workshop will review strategies for optimizing medical communication, enhancing patient adherence and self-efficacy, and creating tailored comprehensive treatment plans including empirically supported behavioral approaches.

## GENERAL INFORMATION

### TARGET AUDIENCE

**This program is designed for neurologists, family practitioners, internal medicine, psychologists, and other health professionals who would like more information on the proper diagnosis and treatment of chronic migraine patients.**

### EDUCATION MISSION STATEMENT

The provision of quality CME is a primary mission of the American Headache Society® (AHS). AHS's educational objectives are to continue to improve the knowledge, skills, and professional performance of physicians, psychologists, and other health professionals in the care of patients with head, neck, and orofacial pain by:

- Providing a forum for presentation of free scientific communication on research and clinical practice
- Providing educational symposia
- Improving education in medical schools and residency programs
- Identifying and developing new educational initiatives
- Supporting educational programs directed to people with head, neck, and orofacial pain
- Maintaining strict adherence to ACCME guidelines
- Developing educational activities and tools that are designed, and then evaluated, for their role in improving the learners' competence, performance and the overall quality and safety of the care they give to individuals suffering from head, neck and orofacial pain.

### CONTINUING MEDICAL EDUCATION CREDIT

CME Statement: AHS is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to sponsor continuing medical education for physicians. AHS takes responsibility for the content, quality, and scientific integrity of this CME activity. AHS designates AMA PRA Category 1 credit(s)<sup>™</sup> for this medical education activity, Comprehensive Migraine Education Program, for a maximum of 4.00 AMA PRA Category 1 Credit(s)<sup>™</sup> for the morning program, 3.5 AMA PRA Category 1 Credit(s)<sup>™</sup> for Workshop 1 and 3.5 AMA PRA Category 1 Credit(s)<sup>™</sup> for Workshop 2.

*Application for CME credit has been filed with the American Academy of Family Physicians (AAFP). Determination of credit is pending.*

Physicians should claim only the credit commensurate with the extent of their participation in the activity.

### DISCLOSURE STATEMENT

All contributors who can affect American Headache Society CME content (including but not limited to Leadership, Program Chairs, Program Committee Members, Moderators, Faculty, Speakers, Reviewers, Teachers, Authors, Medical Writers and Staff), in their respective roles, are required to disclose all relevant financial relationships with any commercial interest that could be viewed as a real or perceived conflict of interest. Contributors will also identify relevant financial relationships of their spouse, partner or immediate family.

This policy is in effect to maintain adherence with the conflict of interest guidelines set by the Accreditation Council for Continuing Medical Education (ACCME) and the American Headache Society Ethics Committee.

Prior to the program, attendees will be made aware of the presence or absence of relevant financial relationships for any contributors who may affect the development, management, presentation or evaluation of the CME activity. The presence or absence of relevant financial relationships for any contributor who affects content are listed in the Final Program, mobile app (where applicable), presented verbally and in slide form.

Individuals who refuse to disclose relevant financial relationships will be disqualified from being a contributor and cannot have control of, or responsibility for, the development, management presentation or evaluation of the CME activity.

### SPECIAL NOTE FOR THE PHYSICALLY CHALLENGED

The American Headache Society® wishes to take steps to ensure that no individual with disability is excluded, denied services, segregated, or otherwise treated differently than other individuals because of the absence of auxiliary aids and services. If you need any auxiliary aids or services identified in the Americans with Disabilities Act, or any assistance in registering for this symposium, please contact AHSQ at 856-423-0043, write AHS, 19 Mantua Road, Mt. Royal, NJ, 08061, or email [AHSQ@talley.com](mailto:AHSQ@talley.com).

### REGISTRATION

To register, at no cost to the healthcare professional, [click here](#).

[www.AmericanHeadacheSociety.org](http://www.AmericanHeadacheSociety.org)